Aptamers

The emerging class of future anticoagulation for vascular disease

Wiktor Kuliczkowski, James Floyd, Alex Malinin, Victor Serebruany

Research output: Contribution to journalArticle

Abstract

Anticoagulation is an important therapeutic strategy to treat and prevent recurrent thrombotic events in patients after acute myocardial infarction and ischemic stroke. However, available anticoagulants have numerous shortcomings including hemorrhage risks, limited clinical application including heparin-induced thrombocytopenia and modest therapeutic benefit. Each component of the coagulation cascade is a potential target for new drug developments. Representing an attractive new therapeutic class, aptamers are nucleic acid ligand with a high affinity and specificity for proteins involved in the clot growth. Potential antidote control of aptamer activity offers an important advance in anticoagulant safety. Aptamers are a promising class of compounds, both for target validation and therapy. As designer drugs, they exhibit high specificity, high affinity and modifiable bioavailability. The ability to generate inhibitors with such properties against a variety of target proteins will be valuable as the human genome and proteome are deciphered. This article summarizes current knowledge of aptamers developed against coagulation proteins, focusing on the biology, pharmacology, preclinical and early clinical experience with this novel class of anticoagulants.

Original languageEnglish (US)
Pages (from-to)503-507
Number of pages5
JournalExpert Review of Cardiovascular Therapy
Volume8
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Vascular Diseases
Anticoagulants
Designer Drugs
Antidotes
Proteins
Human Genome
Proteome
Therapeutics
Thrombocytopenia
Nucleic Acids
Biological Availability
Heparin
Stroke
Myocardial Infarction
Pharmacology
Hemorrhage
Ligands
Safety
Growth
Pharmaceutical Preparations

Keywords

  • Anticoagulants
  • Aptamer
  • Clinical trial
  • Oligonucleotides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Aptamers : The emerging class of future anticoagulation for vascular disease. / Kuliczkowski, Wiktor; Floyd, James; Malinin, Alex; Serebruany, Victor.

In: Expert Review of Cardiovascular Therapy, Vol. 8, No. 4, 04.2010, p. 503-507.

Research output: Contribution to journalArticle

Kuliczkowski, Wiktor ; Floyd, James ; Malinin, Alex ; Serebruany, Victor. / Aptamers : The emerging class of future anticoagulation for vascular disease. In: Expert Review of Cardiovascular Therapy. 2010 ; Vol. 8, No. 4. pp. 503-507.
@article{ac570cd19a584079afa79c33a95c458d,
title = "Aptamers: The emerging class of future anticoagulation for vascular disease",
abstract = "Anticoagulation is an important therapeutic strategy to treat and prevent recurrent thrombotic events in patients after acute myocardial infarction and ischemic stroke. However, available anticoagulants have numerous shortcomings including hemorrhage risks, limited clinical application including heparin-induced thrombocytopenia and modest therapeutic benefit. Each component of the coagulation cascade is a potential target for new drug developments. Representing an attractive new therapeutic class, aptamers are nucleic acid ligand with a high affinity and specificity for proteins involved in the clot growth. Potential antidote control of aptamer activity offers an important advance in anticoagulant safety. Aptamers are a promising class of compounds, both for target validation and therapy. As designer drugs, they exhibit high specificity, high affinity and modifiable bioavailability. The ability to generate inhibitors with such properties against a variety of target proteins will be valuable as the human genome and proteome are deciphered. This article summarizes current knowledge of aptamers developed against coagulation proteins, focusing on the biology, pharmacology, preclinical and early clinical experience with this novel class of anticoagulants.",
keywords = "Anticoagulants, Aptamer, Clinical trial, Oligonucleotides",
author = "Wiktor Kuliczkowski and James Floyd and Alex Malinin and Victor Serebruany",
year = "2010",
month = "4",
doi = "10.1586/erc.09.182",
language = "English (US)",
volume = "8",
pages = "503--507",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Aptamers

T2 - The emerging class of future anticoagulation for vascular disease

AU - Kuliczkowski, Wiktor

AU - Floyd, James

AU - Malinin, Alex

AU - Serebruany, Victor

PY - 2010/4

Y1 - 2010/4

N2 - Anticoagulation is an important therapeutic strategy to treat and prevent recurrent thrombotic events in patients after acute myocardial infarction and ischemic stroke. However, available anticoagulants have numerous shortcomings including hemorrhage risks, limited clinical application including heparin-induced thrombocytopenia and modest therapeutic benefit. Each component of the coagulation cascade is a potential target for new drug developments. Representing an attractive new therapeutic class, aptamers are nucleic acid ligand with a high affinity and specificity for proteins involved in the clot growth. Potential antidote control of aptamer activity offers an important advance in anticoagulant safety. Aptamers are a promising class of compounds, both for target validation and therapy. As designer drugs, they exhibit high specificity, high affinity and modifiable bioavailability. The ability to generate inhibitors with such properties against a variety of target proteins will be valuable as the human genome and proteome are deciphered. This article summarizes current knowledge of aptamers developed against coagulation proteins, focusing on the biology, pharmacology, preclinical and early clinical experience with this novel class of anticoagulants.

AB - Anticoagulation is an important therapeutic strategy to treat and prevent recurrent thrombotic events in patients after acute myocardial infarction and ischemic stroke. However, available anticoagulants have numerous shortcomings including hemorrhage risks, limited clinical application including heparin-induced thrombocytopenia and modest therapeutic benefit. Each component of the coagulation cascade is a potential target for new drug developments. Representing an attractive new therapeutic class, aptamers are nucleic acid ligand with a high affinity and specificity for proteins involved in the clot growth. Potential antidote control of aptamer activity offers an important advance in anticoagulant safety. Aptamers are a promising class of compounds, both for target validation and therapy. As designer drugs, they exhibit high specificity, high affinity and modifiable bioavailability. The ability to generate inhibitors with such properties against a variety of target proteins will be valuable as the human genome and proteome are deciphered. This article summarizes current knowledge of aptamers developed against coagulation proteins, focusing on the biology, pharmacology, preclinical and early clinical experience with this novel class of anticoagulants.

KW - Anticoagulants

KW - Aptamer

KW - Clinical trial

KW - Oligonucleotides

UR - http://www.scopus.com/inward/record.url?scp=77951218739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951218739&partnerID=8YFLogxK

U2 - 10.1586/erc.09.182

DO - 10.1586/erc.09.182

M3 - Article

VL - 8

SP - 503

EP - 507

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 4

ER -